Cas No.: | 1610358-56-9 |
Chemical Name: | (+)-BAY-1251152 |
Synonyms: | 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine;(+)-5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine;BCP29512;BCP33292;NSC802450;BAY1251152;(Inverted exclamation markA)-BAY-1251152;(+)-BAY-1251152 |
SMILES: | S(C)(CC1C=CN=C(C=1)NC1C=C(C(=CN=1)F)C1C=CC(=CC=1OC)F)(=N)=O |
Formula: | C19H18F2N4O2S |
M.Wt: | 404.4336 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM, displays> 50-fold selectivity against other CDKs;exhibits broad anti-proliferative activity against a panel of tumour cell lines with sub-micromolar IC50 values; demonstrates excellent efficacy in xenograft models (e.g. MOLM13) in mice and rats.Blood CancerPhase 1 Clinical |